Transl Res:王慧和刘宁宁团队发现靶向抗癌药物能增强抗真菌作用

2022-08-26 上海交通大学公共卫生学院 上海交通大学公共卫生学院

近日,上海交通大学医学院公共卫生学院王慧教授和刘宁宁研究员团队联合中科院上海巴斯德研究所陈昌斌教授,在国际知名期刊

图片

近日,上海交通大学医学院公共卫生学院王慧教授和刘宁宁研究员团队联合中科院上海巴斯德研究所陈昌斌教授,在国际知名期刊Translational Research杂志发表了题为A dual action small molecule enhances azoles and overcomes resistance through co-targeting Pdr5 and Vma1的研究论文。发现第三代EGFR抑制剂欧西莫替尼(osimertinib)在抗真菌感染过程中具有双重功能,不仅能够同时靶向白念珠菌Pdr5和Vma1增强氟康唑的抗真菌药效,而且能够同时靶向宿主EGFR受体抑制宿主细胞内吞白念珠菌,从而保护宿主细胞免受白念珠菌的侵袭。这种双重作用为抗真菌感染提供了一种全新的策略和解决方案,有望为真菌感染的预防和治疗提供有效的治疗药物。

每年全世界约有150万人遭受真菌感染,白念珠菌是临床常见的病原真菌,其造成的系统性念珠菌病的发病率和死亡率均较高。白念珠菌感染分为粘膜感染和系统性感染,四分之三的女性在一生中至少经历一次阴道白念珠菌感染,而系统性白念珠菌感染往往出现在免疫缺陷或接受免疫抑制治疗、菌群紊乱、以及有医疗器械植入的患者当中,在医院以及其他医疗机构中具有高发病率和高死亡率,其致死率高达30–50%,在癌症病人中甚至可以高达40%-70%。在美国,白念珠菌每年造成约60000例全身系统性感染病例,直接经济损失高达20–40亿美元。目前抗真菌药物的种类和疗效极为有限,加之真菌的耐药性逐年增加,对人体健康造成巨大威胁,因此临床上对于新型抗真菌药物的研发需求极为迫切。

白念珠菌侵染宿主时,宿主的表皮生长因子受体(EGFR)可以介导上皮细胞对白念珠菌的内吞作用,是真菌侵染宿主的关键过程。然而,是否存在EGFR抑制剂抑制真菌病原体的生长及其作用机制目前尚不清楚。

研究发现,OSI联合FLC对多种真菌耐药株具有广谱抗真菌药效,其一方面可以抑制药物外排泵Pdr5的功能,从而抑制FLC的外排,增加了FLC在细胞内的有效积累,增强其抗真菌药效。同时,OSI还能够靶向结合Vma1 的Ser274,从而破坏细胞内pH稳态,抑制下游TORC1复合物活性,最终导致细胞死亡。

图片

本文第一作者和最后通讯作者单位为上海交通大学医学院。上海交通大学医学院公共卫生学院王慧教授、刘宁宁研究员和中科院上海巴斯德研究所陈昌斌教授为论文共同通讯作者,上海交通大学医学院公共卫生学院刘宁宁研究员、硕士生周佳、中科院上海巴斯德研究所博士生姜彤为论文共同第一作者。纽约州立大学上州医科大学Patricia M Kane教授、上海交通大学医学院公共卫生学院张新宇教授、上海交通大学环境科学与工程学院赵砚彬教授、上海中医药大学曹永兵教授、上海交通大学医学院附属瑞金医院彭奕冰教授、南昌大学黄孝天和曾令兵教授、四川大学任彪教授、麦吉尔大学丁俊教授、哈佛医学院齐婉君博士等为本论文的合作者。该研究得到了国家科技部重点研发计划、国家自然科学基金和上海市科委和卫健委等项目的资助。

原始出处:

Liu NN, Zhou J, Jiang T, Tarsio M, Yu F, Zheng X, Qi W, Liu L, Tan JC, Wei L, Ding J, Li J, Zeng L, Ren B, Huang X, Peng Y, Cao YB, Zhao Y, Zhang XY, Kane PM, Chen C, Wang H.A dual action small molecule enhances azoles and overcomes resistance through co-targeting Pdr5 and Vma1.Transl Res . 2022 Sep;247:39-57. doi: 10.1016/j.trsl.2022.04.002

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1819830, encodeId=179118198301b, content=<a href='/topic/show?id=4db099911f3' target=_blank style='color:#2F92EE;'>#靶向抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99911, encryptionId=4db099911f3, topicName=靶向抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0357291, createdName=xiaoshitou, createdTime=Tue May 30 23:13:28 CST 2023, time=2023-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067642, encodeId=461f206e6429d, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Fri Apr 21 07:13:28 CST 2023, time=2023-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657674, encodeId=272b165e6746d, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Sun Sep 25 19:13:28 CST 2022, time=2022-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819825, encodeId=5ce4181982521, content=<a href='/topic/show?id=9ec7999104d' target=_blank style='color:#2F92EE;'>#靶向抗癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99910, encryptionId=9ec7999104d, topicName=靶向抗癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sun Nov 20 10:13:28 CST 2022, time=2022-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775770, encodeId=9b0e1e75770ed, content=<a href='/topic/show?id=19e45556efa' target=_blank style='color:#2F92EE;'>#抗真菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55567, encryptionId=19e45556efa, topicName=抗真菌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596c38798743, createdName=amy0563, createdTime=Thu Oct 13 03:13:28 CST 2022, time=2022-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308283, encodeId=87fc13082839b, content=<a href='/topic/show?id=6e495554550' target=_blank style='color:#2F92EE;'>#抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55545, encryptionId=6e495554550, topicName=抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Sun Aug 28 05:13:28 CST 2022, time=2022-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314904, encodeId=f5361314904e6, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Aug 28 05:13:28 CST 2022, time=2022-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1353846, encodeId=d9bf1353846f0, content=<a href='/topic/show?id=dddce266537' target=_blank style='color:#2F92EE;'>#真菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72665, encryptionId=dddce266537, topicName=真菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Aug 28 05:13:28 CST 2022, time=2022-08-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1819830, encodeId=179118198301b, content=<a href='/topic/show?id=4db099911f3' target=_blank style='color:#2F92EE;'>#靶向抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99911, encryptionId=4db099911f3, topicName=靶向抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0357291, createdName=xiaoshitou, createdTime=Tue May 30 23:13:28 CST 2023, time=2023-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067642, encodeId=461f206e6429d, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Fri Apr 21 07:13:28 CST 2023, time=2023-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657674, encodeId=272b165e6746d, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Sun Sep 25 19:13:28 CST 2022, time=2022-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819825, encodeId=5ce4181982521, content=<a href='/topic/show?id=9ec7999104d' target=_blank style='color:#2F92EE;'>#靶向抗癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99910, encryptionId=9ec7999104d, topicName=靶向抗癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sun Nov 20 10:13:28 CST 2022, time=2022-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775770, encodeId=9b0e1e75770ed, content=<a href='/topic/show?id=19e45556efa' target=_blank style='color:#2F92EE;'>#抗真菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55567, encryptionId=19e45556efa, topicName=抗真菌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596c38798743, createdName=amy0563, createdTime=Thu Oct 13 03:13:28 CST 2022, time=2022-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308283, encodeId=87fc13082839b, content=<a href='/topic/show?id=6e495554550' target=_blank style='color:#2F92EE;'>#抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55545, encryptionId=6e495554550, topicName=抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Sun Aug 28 05:13:28 CST 2022, time=2022-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314904, encodeId=f5361314904e6, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Aug 28 05:13:28 CST 2022, time=2022-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1353846, encodeId=d9bf1353846f0, content=<a href='/topic/show?id=dddce266537' target=_blank style='color:#2F92EE;'>#真菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72665, encryptionId=dddce266537, topicName=真菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Aug 28 05:13:28 CST 2022, time=2022-08-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1819830, encodeId=179118198301b, content=<a href='/topic/show?id=4db099911f3' target=_blank style='color:#2F92EE;'>#靶向抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99911, encryptionId=4db099911f3, topicName=靶向抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0357291, createdName=xiaoshitou, createdTime=Tue May 30 23:13:28 CST 2023, time=2023-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067642, encodeId=461f206e6429d, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Fri Apr 21 07:13:28 CST 2023, time=2023-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657674, encodeId=272b165e6746d, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Sun Sep 25 19:13:28 CST 2022, time=2022-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819825, encodeId=5ce4181982521, content=<a href='/topic/show?id=9ec7999104d' target=_blank style='color:#2F92EE;'>#靶向抗癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99910, encryptionId=9ec7999104d, topicName=靶向抗癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sun Nov 20 10:13:28 CST 2022, time=2022-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775770, encodeId=9b0e1e75770ed, content=<a href='/topic/show?id=19e45556efa' target=_blank style='color:#2F92EE;'>#抗真菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55567, encryptionId=19e45556efa, topicName=抗真菌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596c38798743, createdName=amy0563, createdTime=Thu Oct 13 03:13:28 CST 2022, time=2022-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308283, encodeId=87fc13082839b, content=<a href='/topic/show?id=6e495554550' target=_blank style='color:#2F92EE;'>#抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55545, encryptionId=6e495554550, topicName=抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Sun Aug 28 05:13:28 CST 2022, time=2022-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314904, encodeId=f5361314904e6, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Aug 28 05:13:28 CST 2022, time=2022-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1353846, encodeId=d9bf1353846f0, content=<a href='/topic/show?id=dddce266537' target=_blank style='color:#2F92EE;'>#真菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72665, encryptionId=dddce266537, topicName=真菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Aug 28 05:13:28 CST 2022, time=2022-08-28, status=1, ipAttribution=)]
    2022-09-25 bsmagic9140
  4. [GetPortalCommentsPageByObjectIdResponse(id=1819830, encodeId=179118198301b, content=<a href='/topic/show?id=4db099911f3' target=_blank style='color:#2F92EE;'>#靶向抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99911, encryptionId=4db099911f3, topicName=靶向抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0357291, createdName=xiaoshitou, createdTime=Tue May 30 23:13:28 CST 2023, time=2023-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067642, encodeId=461f206e6429d, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Fri Apr 21 07:13:28 CST 2023, time=2023-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657674, encodeId=272b165e6746d, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Sun Sep 25 19:13:28 CST 2022, time=2022-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819825, encodeId=5ce4181982521, content=<a href='/topic/show?id=9ec7999104d' target=_blank style='color:#2F92EE;'>#靶向抗癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99910, encryptionId=9ec7999104d, topicName=靶向抗癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sun Nov 20 10:13:28 CST 2022, time=2022-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775770, encodeId=9b0e1e75770ed, content=<a href='/topic/show?id=19e45556efa' target=_blank style='color:#2F92EE;'>#抗真菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55567, encryptionId=19e45556efa, topicName=抗真菌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596c38798743, createdName=amy0563, createdTime=Thu Oct 13 03:13:28 CST 2022, time=2022-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308283, encodeId=87fc13082839b, content=<a href='/topic/show?id=6e495554550' target=_blank style='color:#2F92EE;'>#抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55545, encryptionId=6e495554550, topicName=抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Sun Aug 28 05:13:28 CST 2022, time=2022-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314904, encodeId=f5361314904e6, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Aug 28 05:13:28 CST 2022, time=2022-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1353846, encodeId=d9bf1353846f0, content=<a href='/topic/show?id=dddce266537' target=_blank style='color:#2F92EE;'>#真菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72665, encryptionId=dddce266537, topicName=真菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Aug 28 05:13:28 CST 2022, time=2022-08-28, status=1, ipAttribution=)]
    2022-11-20 lqvr
  5. [GetPortalCommentsPageByObjectIdResponse(id=1819830, encodeId=179118198301b, content=<a href='/topic/show?id=4db099911f3' target=_blank style='color:#2F92EE;'>#靶向抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99911, encryptionId=4db099911f3, topicName=靶向抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0357291, createdName=xiaoshitou, createdTime=Tue May 30 23:13:28 CST 2023, time=2023-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067642, encodeId=461f206e6429d, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Fri Apr 21 07:13:28 CST 2023, time=2023-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657674, encodeId=272b165e6746d, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Sun Sep 25 19:13:28 CST 2022, time=2022-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819825, encodeId=5ce4181982521, content=<a href='/topic/show?id=9ec7999104d' target=_blank style='color:#2F92EE;'>#靶向抗癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99910, encryptionId=9ec7999104d, topicName=靶向抗癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sun Nov 20 10:13:28 CST 2022, time=2022-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775770, encodeId=9b0e1e75770ed, content=<a href='/topic/show?id=19e45556efa' target=_blank style='color:#2F92EE;'>#抗真菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55567, encryptionId=19e45556efa, topicName=抗真菌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596c38798743, createdName=amy0563, createdTime=Thu Oct 13 03:13:28 CST 2022, time=2022-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308283, encodeId=87fc13082839b, content=<a href='/topic/show?id=6e495554550' target=_blank style='color:#2F92EE;'>#抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55545, encryptionId=6e495554550, topicName=抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Sun Aug 28 05:13:28 CST 2022, time=2022-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314904, encodeId=f5361314904e6, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Aug 28 05:13:28 CST 2022, time=2022-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1353846, encodeId=d9bf1353846f0, content=<a href='/topic/show?id=dddce266537' target=_blank style='color:#2F92EE;'>#真菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72665, encryptionId=dddce266537, topicName=真菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Aug 28 05:13:28 CST 2022, time=2022-08-28, status=1, ipAttribution=)]
    2022-10-13 amy0563
  6. [GetPortalCommentsPageByObjectIdResponse(id=1819830, encodeId=179118198301b, content=<a href='/topic/show?id=4db099911f3' target=_blank style='color:#2F92EE;'>#靶向抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99911, encryptionId=4db099911f3, topicName=靶向抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0357291, createdName=xiaoshitou, createdTime=Tue May 30 23:13:28 CST 2023, time=2023-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067642, encodeId=461f206e6429d, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Fri Apr 21 07:13:28 CST 2023, time=2023-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657674, encodeId=272b165e6746d, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Sun Sep 25 19:13:28 CST 2022, time=2022-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819825, encodeId=5ce4181982521, content=<a href='/topic/show?id=9ec7999104d' target=_blank style='color:#2F92EE;'>#靶向抗癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99910, encryptionId=9ec7999104d, topicName=靶向抗癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sun Nov 20 10:13:28 CST 2022, time=2022-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775770, encodeId=9b0e1e75770ed, content=<a href='/topic/show?id=19e45556efa' target=_blank style='color:#2F92EE;'>#抗真菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55567, encryptionId=19e45556efa, topicName=抗真菌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596c38798743, createdName=amy0563, createdTime=Thu Oct 13 03:13:28 CST 2022, time=2022-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308283, encodeId=87fc13082839b, content=<a href='/topic/show?id=6e495554550' target=_blank style='color:#2F92EE;'>#抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55545, encryptionId=6e495554550, topicName=抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Sun Aug 28 05:13:28 CST 2022, time=2022-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314904, encodeId=f5361314904e6, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Aug 28 05:13:28 CST 2022, time=2022-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1353846, encodeId=d9bf1353846f0, content=<a href='/topic/show?id=dddce266537' target=_blank style='color:#2F92EE;'>#真菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72665, encryptionId=dddce266537, topicName=真菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Aug 28 05:13:28 CST 2022, time=2022-08-28, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1819830, encodeId=179118198301b, content=<a href='/topic/show?id=4db099911f3' target=_blank style='color:#2F92EE;'>#靶向抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99911, encryptionId=4db099911f3, topicName=靶向抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0357291, createdName=xiaoshitou, createdTime=Tue May 30 23:13:28 CST 2023, time=2023-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067642, encodeId=461f206e6429d, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Fri Apr 21 07:13:28 CST 2023, time=2023-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657674, encodeId=272b165e6746d, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Sun Sep 25 19:13:28 CST 2022, time=2022-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819825, encodeId=5ce4181982521, content=<a href='/topic/show?id=9ec7999104d' target=_blank style='color:#2F92EE;'>#靶向抗癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99910, encryptionId=9ec7999104d, topicName=靶向抗癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sun Nov 20 10:13:28 CST 2022, time=2022-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775770, encodeId=9b0e1e75770ed, content=<a href='/topic/show?id=19e45556efa' target=_blank style='color:#2F92EE;'>#抗真菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55567, encryptionId=19e45556efa, topicName=抗真菌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596c38798743, createdName=amy0563, createdTime=Thu Oct 13 03:13:28 CST 2022, time=2022-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308283, encodeId=87fc13082839b, content=<a href='/topic/show?id=6e495554550' target=_blank style='color:#2F92EE;'>#抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55545, encryptionId=6e495554550, topicName=抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Sun Aug 28 05:13:28 CST 2022, time=2022-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314904, encodeId=f5361314904e6, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Aug 28 05:13:28 CST 2022, time=2022-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1353846, encodeId=d9bf1353846f0, content=<a href='/topic/show?id=dddce266537' target=_blank style='color:#2F92EE;'>#真菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72665, encryptionId=dddce266537, topicName=真菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Aug 28 05:13:28 CST 2022, time=2022-08-28, status=1, ipAttribution=)]
    2022-08-28 sunylz
  8. [GetPortalCommentsPageByObjectIdResponse(id=1819830, encodeId=179118198301b, content=<a href='/topic/show?id=4db099911f3' target=_blank style='color:#2F92EE;'>#靶向抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99911, encryptionId=4db099911f3, topicName=靶向抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0357291, createdName=xiaoshitou, createdTime=Tue May 30 23:13:28 CST 2023, time=2023-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067642, encodeId=461f206e6429d, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Fri Apr 21 07:13:28 CST 2023, time=2023-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657674, encodeId=272b165e6746d, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Sun Sep 25 19:13:28 CST 2022, time=2022-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819825, encodeId=5ce4181982521, content=<a href='/topic/show?id=9ec7999104d' target=_blank style='color:#2F92EE;'>#靶向抗癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99910, encryptionId=9ec7999104d, topicName=靶向抗癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sun Nov 20 10:13:28 CST 2022, time=2022-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775770, encodeId=9b0e1e75770ed, content=<a href='/topic/show?id=19e45556efa' target=_blank style='color:#2F92EE;'>#抗真菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55567, encryptionId=19e45556efa, topicName=抗真菌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596c38798743, createdName=amy0563, createdTime=Thu Oct 13 03:13:28 CST 2022, time=2022-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308283, encodeId=87fc13082839b, content=<a href='/topic/show?id=6e495554550' target=_blank style='color:#2F92EE;'>#抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55545, encryptionId=6e495554550, topicName=抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Sun Aug 28 05:13:28 CST 2022, time=2022-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314904, encodeId=f5361314904e6, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Aug 28 05:13:28 CST 2022, time=2022-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1353846, encodeId=d9bf1353846f0, content=<a href='/topic/show?id=dddce266537' target=_blank style='color:#2F92EE;'>#真菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72665, encryptionId=dddce266537, topicName=真菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Aug 28 05:13:28 CST 2022, time=2022-08-28, status=1, ipAttribution=)]
    2022-08-28 zhaojie88

相关资讯

Front Oncol:EGFR-TKI联合胸腺素治疗EGFR突变的晚期非小细胞肺癌(NSCLC)可改善患者的预后

研究表明,EGFR-TKI联合胸腺素治疗可改善EGFR突变的晚期非小细胞肺癌(NSCLC)患者的PFS和OS。

第二个国产三代EGFR-TKI获批上市

据国家药监局官网最新消息,艾力斯的核心产品——不可逆、高选择性第三代EGFR抑制剂甲磺酸伏美替尼片获批上市,该产品是目前市面上获批上市的第三个第三代EGFR-TKI,也是艾力斯

Eur J Cancer: 循环肿瘤DNA(ctDNA)鉴别EGFR突变的NSCLC从EGFR-TKI连续治疗中获益的人群

治疗前的ctDNA水平有助于鉴别低危EGFR+NSCLC患者,从而在EGFR-TKI的连续治疗中获益。

Clin Cancer Res:第三代EGFR-TKI Abvertinib治疗EGFR T790M+ NSCLC的活性和安全性

Abvertinib 300mg(2/日)在携带EGFR T790M突变的NSCLC患者中具有可观的临床活性,而且副反应可控

NSCLC术后复发转移的诊疗仍有难点,三代EGFR-TKI或可助力突破现状

手术是非小细胞肺癌(NSCLC)实现治愈的主要手段,然而局部晚期尤其是ⅢA(N2)期的NSCLC患者,术后仍然面临很高的复发转移风险。特邀北京大学肿瘤医院的康晓征副教授对NSCLC术后复发转移的诊疗现状、后续治疗方案的考虑因素和二次手术的判断依据等热点问题进行解读。

Front Oncol:EGFR突变NSCLC患者EGFR-TKI治疗进展后MET扩增患者的不同治疗策略的疗效探索

该真实世界回顾性研究表表明,EGFR和MET双重抑制可能是EGFR-TKI治疗耐药后的有效治疗方式。